FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2280596326> ?p ?o ?g. }

• W2280596326 abstract "3071 Background: Individuals of advanced chronological age exhibit an impaired immune response to vaccines. This may be due to a reduction in the ratio of antigen naïve/memory CD4 and CD8 T cells and acquisition of functional defects in activated “helper” CD4 T cells (eg diminished CD40 ligand (CD40L) expression) during the aging process. Methods: In order to circumvent this defective response to vaccines in individuals in the fifth and sixth decades of life, our laboratory has developed an adenoviral vector (Ad-sig- TAA/ecdCD40L) vaccine which is designed for the in vivo target associated antigen (TAA) loading and activation of dendritic cells (DCs), and to overcome the absence of CD40L expression in activated CD4 helper T cells in older individuals. Results: The subcutaneous (sc) injection of this vector leads to the release of a fusion protein composed of a TAA linked to the extracellular domain (ecd) of the CD40 ligand (CD40L), which binds to the CD40 receptor on DCs, activates the DCs, and leads to the presentation of TAA fragments on Class I MHC. Two sc injections of the TAA/ecdCD40L protein as a booster following the sc administration of the Ad-sig-TAA/ecdCD40L vector (VPP) expands the magnitude of the cellular and humoral immune response induced by the vector in 18 month old aged mice as well as in younger mice. This vaccine decreased levels of negative regulatory CD4 FOXP3 T cells in tumor nodules. We administered TBI and an allogeneic stem cell transplant 7 days post sc injection of the E7 positive TC-1 cells. DLI from an Ad-sig-E7/ecdCD40L vector prime-E7/ecdCD40L protein boost vaccinated donor were injected iv 3 days post transplant, and a single E7/ecdCD40L protein boost sc vaccination one week thereafter. We found that the growth rate of the E7 positive TC-1 tumor cells post allograft was less in the vaccinated than in the control (injection of tumor cells followed in 7 days by TBI), or the animals in which the allograft recipient was vaccinated without DLI. Conclusions: Thus, the use of DLI from VPP vaccinated allodonors decreased tumor cell growth post allograft. No significant financial relationships to disclose." @default.
• W2280596326 created "2016-06-24" @default.
• W2280596326 creator A5000106724 @default.
• W2280596326 creator A5037478865 @default.
• W2280596326 creator A5061917722 @default.
• W2280596326 creator A5082564365 @default.
• W2280596326 creator A5082587956 @default.
• W2280596326 date "2007-06-20" @default.
• W2280596326 modified "2023-09-30" @default.
• W2280596326 title "Donor lymphocyte infusions from Ad-sig-TAA/ecdCD40L vector prime-TAA/ecdCD40L protein boost (VPP) vaccinated allodonors decrease tumor cell growth post allograft" @default.
• W2280596326 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.3071" @default.
• W2280596326 hasPublicationYear "2007" @default.
• W2280596326 type Work @default.
• W2280596326 sameAs 2280596326 @default.
• W2280596326 citedByCount "0" @default.
• W2280596326 crossrefType "journal-article" @default.
• W2280596326 hasAuthorship W2280596326A5000106724 @default.
• W2280596326 hasAuthorship W2280596326A5037478865 @default.
• W2280596326 hasAuthorship W2280596326A5061917722 @default.
• W2280596326 hasAuthorship W2280596326A5082564365 @default.
• W2280596326 hasAuthorship W2280596326A5082587956 @default.
• W2280596326 hasConcept C104317684 @default.
• W2280596326 hasConcept C123894998 @default.
• W2280596326 hasConcept C147483822 @default.
• W2280596326 hasConcept C154317977 @default.
• W2280596326 hasConcept C167672396 @default.
• W2280596326 hasConcept C202751555 @default.
• W2280596326 hasConcept C203014093 @default.
• W2280596326 hasConcept C2776090121 @default.
• W2280596326 hasConcept C2778170410 @default.
• W2280596326 hasConcept C39347974 @default.
• W2280596326 hasConcept C40767141 @default.
• W2280596326 hasConcept C55493867 @default.
• W2280596326 hasConcept C71924100 @default.
• W2280596326 hasConcept C86803240 @default.
• W2280596326 hasConcept C8891405 @default.
• W2280596326 hasConceptScore W2280596326C104317684 @default.
• W2280596326 hasConceptScore W2280596326C123894998 @default.
• W2280596326 hasConceptScore W2280596326C147483822 @default.
• W2280596326 hasConceptScore W2280596326C154317977 @default.
• W2280596326 hasConceptScore W2280596326C167672396 @default.
• W2280596326 hasConceptScore W2280596326C202751555 @default.
• W2280596326 hasConceptScore W2280596326C203014093 @default.
• W2280596326 hasConceptScore W2280596326C2776090121 @default.
• W2280596326 hasConceptScore W2280596326C2778170410 @default.
• W2280596326 hasConceptScore W2280596326C39347974 @default.
• W2280596326 hasConceptScore W2280596326C40767141 @default.
• W2280596326 hasConceptScore W2280596326C55493867 @default.
• W2280596326 hasConceptScore W2280596326C71924100 @default.
• W2280596326 hasConceptScore W2280596326C86803240 @default.
• W2280596326 hasConceptScore W2280596326C8891405 @default.
• W2280596326 hasLocation W22805963261 @default.
• W2280596326 hasOpenAccess W2280596326 @default.
• W2280596326 hasPrimaryLocation W22805963261 @default.
• W2280596326 hasRelatedWork W1217682272 @default.
• W2280596326 hasRelatedWork W1545583588 @default.
• W2280596326 hasRelatedWork W1591368579 @default.
• W2280596326 hasRelatedWork W1630570293 @default.
• W2280596326 hasRelatedWork W2002247580 @default.
• W2280596326 hasRelatedWork W2020485605 @default.
• W2280596326 hasRelatedWork W2056133937 @default.
• W2280596326 hasRelatedWork W2090560810 @default.
• W2280596326 hasRelatedWork W2145562912 @default.
• W2280596326 hasRelatedWork W2367344610 @default.
• W2280596326 isParatext "false" @default.
• W2280596326 isRetracted "false" @default.
• W2280596326 magId "2280596326" @default.
• W2280596326 workType "article" @default.